Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment

References

• Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–261. doi:10.1016/j.jhep.2019.08.025
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Yau T, Kang YK, Kim TY, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol. 2019;37:4012. doi:10.1200/JCO.2019.37.15_suppl.4012
   Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi:10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074. doi:10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093–1102. doi:10.1038/onc.2009.416
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. doi:10.1200/JCO.2010.30.5037
   PubMed Web of Science ®Google Scholar
• Laghi L, Bianchi P, Miranda E, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009;10(9):877–884. doi:10.1016/S1470-2045(09)70186-X
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm1093
   PubMed Web of Science ®Google Scholar
• Taisuke Y, Yoshifumi B, Takatsugu I, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resectes esophageal cancer. Ann Surg. 2019;269(3):471–478. doi:10.1097/SLA.0000000000002616
   PubMed Web of Science ®Google Scholar
• Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27(2):407–414. doi:10.1002/hep.510270214
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yao S, Iliopoulou BP, et al. B7-H5 costimulates human T cells via CD28H. Nat Commun. 2013;4:2043. doi:10.1038/ncomms3043
   PubMed Web of Science ®Google Scholar
• Zhao R, Chinai JM, Buhl S, et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci USA. 2013;110(24):9879–9884. doi:10.1073/pnas.1303524110
   PubMed Web of Science ®Google Scholar
• Janakiram M, Chinai JM, Fineberg S, et al. Expression, clinica significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res. 2015;21(10):2359–2366. doi:10.1158/1078-0432.CCR-14-1495
   PubMed Web of Science ®Google Scholar
• Cheng H, Janakiram M, Borczuk A, et al. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res. 2017;23(3):825–832. doi:10.1158/1078-0432.CCR-15-3071
   PubMed Web of Science ®Google Scholar
• Koirala P, Roth ME, Gill J, et al. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep. 2016;6:31154. doi:10.1038/srep31154
   PubMed Web of Science ®Google Scholar
• Lin G, Ye H, Wang J, et al. Immune checkpoint human endogenous retrovirus-H long terminal repeat-associating protein 2 is upregulated and independently predicts unfavorable prognosis in bladder urothelial carcinoma. Nephron. 2019;141(4):256–264. doi:10.1159/000495887
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu D, Feng J, et al. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients. Cancer Cell Int. 2019;19:101. doi:10.1186/s12935-019-0813-2
   PubMed Web of Science ®Google Scholar
• Chen D, Chen W, Xu Y, et al. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. J Med Genet. 2019;56(1):43–49. doi:10.1136/jmedgenet-2018-105454
   PubMed Web of Science ®Google Scholar
• Zhu Z, Dong W. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther. 2018;11:1563–1570. doi:10.2147/OTT.S160493
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive. Adv Anat Pathol. 2017;24(5):235–251. doi:10.1097/PAP.0000000000000162
   PubMed Web of Science ®Google Scholar
• Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: tILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24(6):311–335. doi:10.1097/PAP.0000000000000161
   PubMed Web of Science ®Google Scholar
• McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716–721.
   PubMed Web of Science ®Google Scholar
• Jung HI, Jeong D, Ji S, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 2017;49(1):246–254. doi:10.4143/crt.2016.066
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–2145. doi:10.1158/0008-5472.CAN-15-0255
   PubMed Web of Science ®Google Scholar
• Arneth B. Tumor microenvironment. Medicina. 2019;56(1):15. doi:10.3390/medicina56010015
   PubMed Web of Science ®Google Scholar
• Mcdermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662–673. doi:10.1002/cam4.106
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39(1):26–42. doi:10.1055/s-0038-1676806
   PubMed Web of Science ®Google Scholar
• Mager DL, Hunter DG, Schertzer M, Freeman JD. Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3). Genomics. 1999;59(3):255–263. doi:10.1006/geno.1999.5877
   PubMed Web of Science ®Google Scholar
• Janakiram M, Chinai JM, Zhao A, et al. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. OncoImmunology. 2015;4(8):e1026534. doi:10.1080/2162402X.2015.1026534
   PubMed Web of Science ®Google Scholar
• Farrag MS, Ibrahim EM, El-Hadidy TA, et al. Human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) is a novel immune checkpoint protein in lung cancer which predicts survival. Asian Pac J Cancer Prev. 2021;22(6):1883–1889. doi:10.31557/APJCP.2021.22.6.1883
   PubMedGoogle Scholar
• Yuan Z, Gardiner JC, Maggi EC, et al. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors. Endocr Relat Cancer. 2021;28(2):135–149. doi:10.1530/ERC-20-0337
   PubMed Web of Science ®Google Scholar
• Byun JM, Cho HJ, Park HY, et al. The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma. Medicine. 2021;100(1):e23691. doi:10.1097/MD.0000000000023691
   PubMed Web of Science ®Google Scholar
• Luo M, Xiong Y, Lin Y, et al. H Long Terminal Repeat-Associating 2 (HHLA2) is a biomarker of advanced stage hepatocellular carcinoma and promotes tumor cell development in vitro. Med Sci Monit. 2021;27:e930215. doi:10.12659/MSM.930215
   PubMed Web of Science ®Google Scholar
• Muenphon K, Limpaiboon T, Jearanaikoon P, et al. Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World J Gastroenterol. 2006;12(26):4143–4148. doi:10.3748/wjg.v12.i26.4143
   PubMed Web of Science ®Google Scholar
• Lu Y, Ren J. Advance in trefoil factor family. World Chin J Digestol. 2003;11(18):2019–2021.
   Google Scholar
• Zhang Y, Zhao X, Deng L, et al. High expression of FABP4 and FABP6 in patients with colorectal cancer. World J Surg Oncol. 2019;17(1):171. doi:10.1186/s12957-019-1714-5
   PubMed Web of Science ®Google Scholar
• Ohmachi T, Inoue H, Mimori K, et al. Fatty acid binding protein 6 is overexpressed in colorectal cancer. Clin Cancer Res. 2006;12(17):5090–5095. doi:10.1158/1078-0432.CCR-05-2045
   PubMed Web of Science ®Google Scholar
• Eskandari E, Mahjoubi F, Motalebzadeh J. An integrated study on TFs and miRNAs in colorectal cancer metastasis and evaluation of three co-regulated candidate genes as prognostic markers. Gene. 2018;679:150–159. doi:10.1016/j.gene.2018.09.003
   PubMed Web of Science ®Google Scholar
• Dahan R, Sega E, Engelhardt J, et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28(3):285–295. doi:10.1016/j.ccell.2015.08.004
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–3491. doi:10.1182/blood-2013-05-504043
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102(4):639–644. doi:10.1038/sj.bjc.6605530
   PubMed Web of Science ®Google Scholar
• Jang MK, Kim HS, Chung YH. Clinical aspects of tumor necrosis factor-α signaling in hepatocellular carcinoma. Curr Pharm Des. 2014;20(17):2799–2808. doi:10.2174/13816128113199990587
   PubMed Web of Science ®Google Scholar
• Zhou QH, Li KW, Chen X, et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000157. doi:10.1136/jitc-2019-000157
   PubMed Web of Science ®Google Scholar
• Jing CY, Fu YP, Yi Y, et al. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. J Immunother Cancer. 2019;7(1):77. doi:10.1186/s40425-019-0554-8
   PubMed Web of Science ®Google Scholar
• Cheng HY, Borczuk A, Janakiram M, et al. Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1-negative human lung cancers. Clin Cancer Res. 2018;24(8):1954–1964. doi:10.1158/1078-0432.CCR-17-2924
   PubMed Web of Science ®Google Scholar
• Yoshito W, Osamuv N, Rumikob K, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998;27(2):407–414. doi:10.1002/hep.510270214
   PubMed Web of Science ®Google Scholar
• Campbell KS. Mystery checkpoint revealed: KIR3DL3 finally found a ligand in HHLA2. Cancer Immunol Res. 2021;9(2):128. doi:10.1158/2326-6066.CIR-20-0996
   PubMed Web of Science ®Google Scholar
• Wei Y, Ren X, Galbo PM, et al. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Sci Immunol. 2021;6(61):eabf9792. doi:10.1126/sciimmunol.abf9792
   PubMed Web of Science ®Google Scholar